What to Do After an Accident: Edward Graves of Edward M. Graves III Accident and Injury Law Shares Critical Guidance in HelloNation
Graves underscores the importance of promptly gathering and preserving evidence related to your case. A thorough and timely investigation can be critical, such as obtaining witness statements, videos of the accident from nearby security cameras, obtaining blackbox data before it is destroyed, and documenting the scene and your injuries with photographs at the appropriate time. These steps will help to establish key facts from the outset. He also highlights the necessity of seeking medical attention promptly and following up in a timely manner for all necessary medical treatment. Proper medical care not only safeguards health but the records generated also serve as vital evidence for legal proceedings.
The article advises prompt reporting of the incident to appropriate authorities. Official documentation plays a crucial role in verifying events, parties involved, and witnesses. Graves also cautions against discussing fault or incident details with others involved or their insurance representatives, as such statements may later be misinterpreted or misused. Keeping a detailed personal journal of the incident, including symptoms and related expenses, ensures a comprehensive record that supports both medical recovery and legal claims.
Through his article, Essential Steps to Take Immediately After an Accident, Graves offers a roadmap for anyone facing the confusion and stress of an unexpected accident, reinforcing the idea that early, informed actions are key to protecting one's well-being and legal standing.
About HelloNation
HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative 'edvertising' approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.
Patrick McCabe
[email protected]
www.hellonation.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1e3c4396-e96c-4516-b368-512ac38dfeec
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Blade Exits Air Taxi Space, Sells Unit To Joby To Focus On Medical Logistics
Blade Air Mobility Inc. (NASDAQ:BLDE) on Monday announced that it is offloading its passenger transportation business to Joby Aviation Inc. (NYSE:JOBY) in a deal valued up to $125 million, aiming to sharpen its focus exclusively on medical air transport and logistics. The transaction includes Blade's U.S. and European passenger operations, airport terminals, and lounges, which will continue under Joby as a standalone unit. Following the sale, Blade will rebrand as Strata Critical Medical, a public company focused on time-sensitive medical logistics. Its medical division, Trinity Medical Solutions, one of the largest air transporters of human organs in the U.S., will remain a wholly owned subsidiary. Also Read: Strata aims to scale its asset-light platform through organic expansion and strategic acquisitions, serving hospitals and healthcare networks. Company executives noted that 84% of 2024's segment-level adjusted EBITDA came from its medical business. The company has also maintained 100% customer retention over the past year among transplant hospitals. 'This divestiture allows us to focus entirely on Medical, our fastest growing and most profitable business line, which represented approximately 84% and 59% of 2024 Segment Adjusted EBITDA and Revenue, respectively,' said Will Heyburn, Blade's Chief Financial Officer. 'Following the close, Strata will be a pure-play, contractual medical business operating in rapidly growing markets that are not correlated with the overall macro environment.' For Joby, the deal provides immediate access to urban aviation infrastructure and a base of over 50,000 annual fliers. Blade's terminals at JFK, Newark, and key New York City locations will aid Joby in accelerating commercial rollout ahead of its first passenger flights in Dubai next year. As part of the deal, Joby will serve as the preferred VTOL partner for Blade's organ transport unit. 'This is a strategically important acquisition that will support the successful launch of Joby's commercial operations in Dubai, our subsequent global rollout and our continued leadership in the sector,' commented JoeBen Bevirt, founder and CEO, Joby Aviation. Joby also recently teamed up with L3Harris to build hybrid military aircraft, boosting its presence in the defense sector and signaling further diversification beyond consumer eVTOL services. Blade CEO Rob Wiesenthal will move to Joby to lead the acquired business and serve as chairman of Strata. Blade CFO Will Heyburn and President Melissa Tomkiel will act as co-CEOs of Strata. The payment structure includes up to $125 million in stock or cash, with $35 million contingent on performance goals and retention benchmarks. A new ticker for Strata will be announced post-close and is expected in the coming weeks. JOBY held cash and cash equivalents of $122.29 million as of March 31, 2025. Related ETFs: ARK Innovation ETF (NYSE:ARKK), SPDR S&P Transportation ETF (NYSE:XTN) Price Action: At last check Monday, JOBY shares were trading higher by 5.94% at $18.18, and BLDR was up 27.72% at $4.79 premarket. Read Next:Photo by T. Schneider via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Blade Exits Air Taxi Space, Sells Unit To Joby To Focus On Medical Logistics originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
29 minutes ago
- Yahoo
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled 'AI and Biotech Take on Brain Cancer.' As Trader Talk describes it: 'When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc's focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC's medical school, and how global clinical trials are expanding the company's reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It's a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.' You can tune in to the episode on Apple Podcasts, Spotify, YouTube, or wherever you listen to your podcasts. ABOUT NEONC TECHNOLOGIES HOLDINGS, Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact:info@ Investor Contact:James CarbonaraHayden IR(646)-755-7412James@
Yahoo
29 minutes ago
- Yahoo
Alan N. Parnes DDS Announces New Website, AcworthDentalCare.com
ACWORTH, Ga., Aug. 4, 2025 /PRNewswire/ -- Alan N. Parnes DDS is thrilled to announce the launch of their new website, Designed with patients in mind, the website offers a user-friendly experience and comprehensive information about the services available at their Acworth, GA dental practice. With more than 39 years of experience, Dr. Alan N. Parnes has built a reputation for providing gentle, personalized dental care to the Acworth community. The practice is dedicated to creating a welcoming environment where patients feel at ease while receiving high-quality care. Their mission is to support overall oral health and well-being through advanced techniques and modern technology. The newly launched website reflects the commitment of Alan N. Parnes DDS to innovation and accessibility. Patients can now explore available services, schedule appointments online, and stay informed about oral health care, all from one convenient online hub. "We're excited to provide our patients with an updated website that makes it easier to connect with our practice," said Dr. Alan N. Parnes. " is designed to be a valuable resource for patients seeking detailed information about our services and philosophy, and we are thrilled to see it come to life." Alan N. Parnes DDS provides a full range of dental services, including: General and family dentistry Cosmetic dentistry Restorative care Dental implants Emergency dental services About Alan N. Parnes DDS Located at 6199 Highway 92, Suite #132, Acworth, GA 30102, Alan N. Parnes DDS is proud to deliver exceptional dental care in an approachable and compassionate setting. To learn more or to schedule an appointment, visit or contact the practice at 770-928-4434. View original content to download multimedia: SOURCE Alan N. Parnes DDS
